Polaryx Therapeutics, Inc. (PLYX)
| Market Cap | 102.68M |
| Revenue (ttm) | n/a |
| Net Income | -6.85M |
| EPS | -0.15 |
| Shares Out | 49.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,308 |
| Open | 2.110 |
| Previous Close | 2.110 |
| Day's Range | 1.970 - 2.138 |
| 52-Week Range | 1.850 - 48.910 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 7.50 (+264.08%) |
| Earnings Date | Aug 13, 2026 |
About PLYX
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was found... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PLYX stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 264.08% from the latest price.
News
Polaryx provides operational readiness update for SOTERIA trial
Polaryx (PLYX) provided an operational readiness update for SOTERIA, its Phase 2 basket trial evaluating PLX-200 across four rare pediatric LSDs. Polaryx continues to advance clinical trial start-up a...
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Company on track to initiate SOTERIA trial in the second half of 2026 Clinical development activities advancing following FDA authorization, CRO engagement and Fast Track Designation across all four p...
Polaryx initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Polaryx (PLYX) with a Strong Buy rating and $6 price target Polaryx is advancing PLX-200 into a Phase 2 basket trial across four rare pediatric…
Polaryx Therapeutics Quarterly report: Q2 2026
Polaryx Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Polaryx Therapeutics Slides: Corporate presentation
Polaryx Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.
Polaryx Therapeutics Proxy statement: Proxy filing
Polaryx Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Polaryx Therapeutics Proxy statement: Proxy filing
Polaryx Therapeutics filed a proxy statement on July 28, 2026, providing details for shareholder voting and corporate governance matters.
Polaryx initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target The company is PLYX developing disease-modifying therapies for rare pediatric lysosomal storage diseases, led b...
Polaryx Therapeutics Slides: Corporate presentation
Polaryx Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2026.
Polaryx initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target PLX-200 uses a long-approved active ingredient and enters SOTERIA with preclinical...
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapi...
Polaryx Therapeutics Quarterly report: Q1 2026
Polaryx Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Stora...
Polaryx Therapeutics Slides: Corporate presentation
Polaryx Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysoso...
Polaryx receives U.S. FDA Fast Track Designation for PLX-200
Polaryx (PLYX) Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis,...
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, toda...
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lyso...
Polaryx Therapeutics Annual report: Q4 2025
Polaryx Therapeutics has published its Q4 2025 annual report on March 24, 2026.
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2
Polaryx (PLYX) announced that the FDA has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis, or LINCL/CLN2 disease. The Fast Track program is...
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric lysosomal st...
Polaryx Therapeutics, Inc trading resumes
11:07 EDT Polaryx (PLYX) Therapeutics, Inc trading resumes
Polaryx Therapeutics, Inc trading halted, volatility trading pause
11:02 EDT Polaryx (PLYX) Therapeutics, Inc trading halted, volatility trading pause
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lyso...